TNF-α promotes gallbladder cancer cell growth and invasion through autocrine mechanisms

GUANGWEI ZHU1,2, QIANG DU1,2, XIAOQIAN WANG1, NANHONG TANG1, FEIFEI SHE2,3 and YANLING CHEN1,2

1Department of Hepatobiliary Surgery, The Affiliated Union Hospital of Fujian Medical University, 2Key Laboratory of Ministry of Education for Gastrointestinal Cancer, 3Key Laboratory of Tumor Microbiology, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, Fujian, P.R. China

Received November 29, 2013; Accepted March 11, 2014

DOI: 10.3892/ijmm.2014.1711

Abstract. Tumor necrosis factor-α (TNF-α) has been suggested to be a putative tumor promoter gene, and autocrine of TNF-α expression has been found in colon cancer and ovarian cancer. As the role of autocrine TNF-α in human gallbladder cancer has not yet been elucidated, the present study examined the expression of TNF-α in gallbladder cancer-derived cell lines. Based on the data, TNF-α mRNA and TNF-α protein expression differed significantly different between the cell lines. In addition, using siRNA targeting TNF-α, the vector, pGPU-GFP-siTNF-α, was constructed and then transfected into the SGC-996 cells (gallbladder cancer cell line) which express high levels of endogenous TNF-α. In vitro experiments indicated that the silencing of TNF-α in the SGC-996 cells significantly suppressed proliferation and invasion. However, apoptosis was not induced by the silencing of TNF-α. Furthermore, we traced the mechanisms underlying these effects and found that the silencing of TNF-α affected the TNF-α-AKT-NF-κB-Bcl-2 pathway in the SGC-996 cells. Our data provide evidence that autocrine TNF-α plays a role as a tumor promoter gene in gallbladder cancer cells, possibly by promoting proliferation and invasion through autocrine mechanisms.

Introduction

Gallbladder cancer is a relatively rare but highly lethal disease and is the most common cancer of the biliary tract and the seventh most common gastrointestinal carcinoma (1). Gallbladder cancer is a highly invasive and aggressive disease with a dismal prognosis and the 5-year survival rate for all stages of gallbladder cancer is approximately 5% (2,3). Gallbladder cancer has a very poor prognosis due to its invasive and aggressive characteristics which are determined by various factors. One of these factors is the tumor microenvironment. Numerous studies have confirmed that tumor necrosis factor-α (TNF-α) is a key cytokine amongst all cytokines of the tumor microenvironment which promote tumor cell proliferation and invasion. In a previous study, in an orthotopic mouse model of pancreatic cancer, treatment with anti-TNF-α antibody resulted the reduction of tumor growth and metastasis (4). In studies on animal thoracic neoplasms, dermatoma and gastrointestinal cancer, the association between tumor cell growth and metastasis and the amount of TNF-α in the tumor microenvironment has been demonstrated (5-7). In patients with malignant tumors of the prostate, it has also been shown that there is a correlation the amount of TNF-α and the degree of malignancy, recurrence, metastasis and prognosis (8). Studies have investigated the effects of TNF-α on tumor cell metastasis, demonstrating that TNF-α enhances the invasive capacity of cancer cells (9,10).

However, the specific mechanisms responsible for TNF-α promoting the progression of malignant tumors have not been elucidated. Certain studies have found that TNF-α promotes a variety of inflammatory cytokines and chemokines, thus affecting the formation and development of tumor blood vessels, promoting tumor invasion and metastasis (11). TNF-α activates associated cell signaling pathways through the activation of transcription factors and related genes, consequently affecting the activity of tumor cells, promoting tumor cell proliferation (12). TNF-α directly leads to gene damage, mutation, amplification of DNA, consequently affecting tumor development (13-15). In addition, TNF changes the function of immune cells, promoting tumor progression (16).

However, there are few reports on the function of tumor-derived TNF-α. Studies on colon and ovarian cancer have found that tumor-derived TNF-α plays an important role in tumor progression (5,11).

However, the specific mechanisms responsible for TNF-α promoting cancer cell growth and invasion are largely unknown. Studies have demonstrated that TNF-α is a key
cytokine amongst all cytokines of the tumor microenvironment. Hagemann et al (17) demonstrated that in epithelial tumors, TNF-α stimulates matrix metalloproteinase (MMP) secretion, thereby promoting tumor cell invasion. Kulbe et al (18) found that in ovarian cancer cells, TNF-α stimulates IL-8, monocyte chemotactic protein-1 (MCP-1) and chemokine receptor expression, thus enhancing tumor cell invasion and metastasis. Chua et al (19) demonstrated that TNF-α enhances epithelial-mesenchymal transition in mammary epithelial cells. Another study also found that TNF-α induces the expression of vascular endothelial growth factor (VEGF), thus promoting microvascularization (20).

Tumor cell-derived TNF-α is a important factor produced by tumor cells and plays a key role in the tumor microenvironment (21). Moreover, TNF-α may even promote tumor growth at lower levels (22). Colon cancer cell-derived TNF-α plays an important role in promoting proliferation through autocrine mechanisms found in the tumor microenvironment (5). In ovarian cancer, it has been shown that tumor-derived TNF-α plays an important role in promoting invasion and metastasis (11,23,24).

However, whether gallbladder cancer cells produce autocrine TNF-α, and whether gallbladder cancer cell-derived TNF-α affects the biological behavior of the cells, remain unresolved issues. Thus, in the present study, we examined various gallbladder cancer cell lines expressing different levels of TNF-α in order to determine the effects of TNF-α on gallbladder cancer proliferation, invasion, metastasis and apoptosis, as well as the underlying mechanisms involved.

Materials and methods

Cell culture. The gallbladder cancer cell line, SGC-996, was provided by the Tumor Cytology Research Unit, Medical College, Tongji University, Shanghai, China. NOZ cells were obtained from the Health Science Research Resources Bank in Japan, and they were isolated from ascites derived from a 48-year-old female patient with gallbladder cancer (25). Both the cell lines were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS). All the cells were incubated at 37˚C under 95% air and 5% CO₂.

Reverse transcription-polymerase chain reaction (RT-PCR). Total RNA was extracted from the gallbladder cells grown in 6-well plates using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. cDNA was synthesized using the AVM First Strand cDNA synthesis kit (Invitrogen). The primers for TNF-α and β-actin were designed according to primer design principles. TNF-α yielded a 443 bp product, and the sequences of the primers were as follows: forward, 5'-AGTGAACAGGCTGTGACCC-3' and reverse, 5'-GCAATGATCCCAAAGTAGACC-3'; TFN receptor 1 (TNFR1) yielded a 223 bp product, and the sequences of the primers were as follows: forward, 5'-TGCCA GGAGAACAGAACA-3' and reverse, 5'-AACCAG TGAAGAGGAGGGAT-3'; and reverse, 5'-AACCAA GCAATGATCCCAAAGTAGACC-3'; RT-PCR was performed under the following conditions: 30 cycles of denaturation at 94˚C for 30 sec, annealing at 55˚C for 30 sec, and extension at 72˚C for 1 min allowed by 10 min for final extension at 72˚C. The data of TNF-α were normalized relative to the expression of β-actin mRNA expression in the respective samples.

Western blot analysis. The cells were washed twice with cold phosphate-buffered saline (PBS) and then incubated on ice with 250 µl of RIPA buffer with 2.5 µl phenylmethylsulfonyl fluoride (PMSF) for 20 min. The cells were collected and centrifuged at 13,000 rpm for 10 min at 4˚C. The protein concentrations of the cell lysates were measured in duplicate using a BCA Protein assay kit (Beyotime Institute of Biotechnology, Shanghai, China). The proportion of protein lysates and 6X loading buffer according to the ratio of 4:1 were mixed and then boiled for 5 min at 100˚C. Equal amounts of total protein were resolved by sodium dodecyl sulfate (SDS) 10%-polyacrylamide gel electrophoresis and transferred onto polyvinylidene fluoride (PVDF) membranes. The PVDF membranes were then blocked with 5% non-fat milk in Tris-buffered saline with Tween-20 (TBST) for 2 h. The diluted primary antibodies, including polyclonal goat anti-human TNFR1 antibody (1:1,000), monoclonal mouse anti-human TNF-α (1:500) (both from Sigma-Aldrich, St. Louis, MO, USA), monoclonal mouse anti-human p-AKT (1:500), monoclonal mouse anti-human p-FOXO-3A (1:500) (all from Cell Signaling Technology, Danvers, MA, USA), monoclonal mouse anti-human β-actin (1:1,000) (all from Santa Cruz Biotechnology, Inc.), were then incubated with the membranes overnight at 4˚C. The appropriate secondary antibody conjugated with horseradish peroxidase diluted in TBST was added for 2 h at room temperature. Using a chemiluminescence western blot immunodetection kit (Invitrogen), we tested immunoreactivity according to the manufacturer's instructions and recorded the data on hyperfilm-ECL detection film. The amounts of TNF-α and TNFR1 protein were semiquantified as ratios to β-actin suggested on each gel.

TNF-α siRNA plasmid construction and transfection. Suitable siRNA target sequences were found in the human TNF-α sequence. According to the design guidelines of siRNA and the literature (5), DNA template oligonucleotides corresponding to siRNA sequences were synthesized as follows: 5'-GCTTGGGACTGTAGAGATAA-3'. A small hairpin RNA (shRNA) of human TNF-α in a pGPU-GFP-neo gene transfer vector encoding a green fluorescent protein (GFP) sequence was constructed by GenePharma Co., Ltd. (Shanghai, China). The plasmids were verified by DNA sequencing. Corresponding sequences (C-N) for the negative controls (NC) were also provided by GenePharma Co., Ltd. The SGC-996 cells were cultured in DMEM medium supplemented with 10% FBS. When the cells were at approximately 90% confluency, we transfected the plasmids into the cells. The cells were transfected using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. The transfection efficiency was quantified by determining the percentage of cells that were GFP-positive using a microscope (Fig. 3A and B). The culture
medium was replaced with a selection medium containing G418 at concentrations of 400 µg/ml (Alexis Biochemicals, San Diego, CA, USA) 72 h later. When we obtained the stably transfected cells, the cells were continuously maintained in 200 µg/ml of G418 (Fig. 3C and D).

Enzyme-linked immunosorbent assay (ELISA). To analyze autocrine TNF-α in the untransfected SGC-996 cells, TNF-α small interfering (siRNA)-transfected SGC-996 cells and the SGC-996 negative control (NC)-transfected cells, these cells were seeded into plates at a density of 3x10⁶ cells/well with 4 ml of DMEM medium supplemented with 10% FBS. The amount of autocrine TNF-α in the cells was determined after 1, 2, 3, 4 and 5 days by ELISA. ELISA was performed to detect TNF-α in the cell culture supernatants of the untransfected SGC-996 cells, the TNF-α siRNA-transfected SGC-996 cells and the SGC-996NC-transfected cells using a TNF-α (H) ELISA kit (Wuhan Boster Biological Technology, Ltd., Wuhan, China). Two hundred microliters of supernatant were added to each well. ELISA was performed according to the manufacturer's instructions. The sensitivity of the assays was 7.8 pg/ml. The absorbance was detected at 450 nm. Each plate test was repeated 3 times.

Cell proliferation assay. To analyze cell proliferation, the untransfected SGC-996, TNF-α siRNA-transfected SGC-996 and SGC-996NC-transfected cells were seeded into 96-well plates at a density of 10⁴ cells/well with 100 µl of DMEM medium supplemented with 10% FBS. The proliferative activity was determined after 1, 2, 3, 4 and 5 days by the addition of 10 µl of MTT (Sigma, St. Louis, MO, USA) to each well. The reaction was terminated after 4 h of incubation at 37°C by the addition of 100 µl of dimethyl sulfoxide (DMSO; Sigma). The optical density (OD) value was obtained by measuring absorbance at a wavelength of 570 nm. Each well test was repeated 6 times.

In vitro cell migration assay. Cell motility was assayed using Transwells (24-well format) with 8 µm pore polycarbonate membranes (BD Biosciences, San Jose, CA, USA). The lower side of the membranes was covered with 5 µg fibronectin (BD Biosciences). To test cell motility induced by TNF-α siRNA, the treated or untreated SGC-996 cells were seeded (5x10⁵/well) in 6-well plates in DMEM medium with 10% FBS for 48 h to collect the cells and stained using the Annexin V-PE/7-aminoactinomycin D kit (KeyGen Biotech, Nanjing, China) according to the manufacturer’s instructions, and analyzed using a Becton-Dickinson FACSCalibur.

Flow cytometric analysis. To determine the apoptosis induced by TNF-α siRNA, the treated or untreated SGC-996 cells were seeded (5x10⁵/well) in 6-well plates in DMEM medium with 10% FBS for 48 h to collect the cells and stained using the Annexin V-PE/7-aminoactinomycin D kit (KeyGen Biotech, Nanjing, China) according to the manufacturer’s instructions, and analyzed using a Becton-Dickinson FACSCalibur.

Statistical analysis. Data were analyzed using GraphPad Prism 5 software. Analysis of variance was conducted followed by one-way ANOVA or an unpaired t-test. The data are expressed as the means ± standard deviation (SD). A P-value <0.05 was considered to indicate a statistically significant difference.

Results

mRNA expression of TNF-α and TNFR1 in the NOZ and SGC-996 cells. We analyzed the mRNA expression of TNF-α and TNFR1 in the NOZ and SGC-996 cells. Using RT-PCR, we detected the mRNA expression of TNF-α and TNFR1 in both cell lines (Fig. 1). The TNF-α mRNA expression level in the NOZ cells was lower than that in the SGC-996 cells (Fig. 1). However, the mRNA levels of TNFR1 were similar between the NOZ and SGC-996 cells (Fig. 1). Thus, we used the SGC-996 cells to further examine the role of autocrine TNF-α.

Protein expression of TNFR1 and TNF-α in the NOZ and SGC-996 cells. We then determined the TNFR1 and TNF-α protein expression in the NOZ and SGC-996 cells by western blot analysis. As expected, the protein expression of TNFR1 and TNF-α was detected in both cell lines. We observed no difference in the TNFR1 protein expression levels in the 2 cell lines by western blot analysis (Fig. 2); however, the TNF-α protein expression level in the NOZ cells was lower than that in the SGC-996 cells.

mRNA and protein expression of TNF-α after obtaining stably transfected SGC-996 (SGC-996si) cells. We used an RNAi-
Figure 2. Protein expression of (A) tumor necrosis factor (TNF) receptor 1 (TNFR1) and (C) TNF-α in the SGC-996 (996) and NOZ cells detected by western blot analysis. TNFR1 and TNF-α protein expression was semiquantified by western blot analysis. The β-actin gene was used as an internal control. (B and D) The densitometric value for both groups were normalized to the internal control and relative expression with the following equation: normalization of both groups/the first normalized value. Data represent the means ± standard deviation (SD), n=3; *P<0.05.

Figure 3. Tumor necrosis factor-α (TNF-α) siRNA plasmid construction and transfection. (A and B) Expression of mock vector green fluorescent protein (GFP) and siTNF-α-GFP was observed at 72 h after transfection by fluorescence microscopy. (C and D) Stable expression of mock vector GFP and siTNF-α-GFP was observed after a screening test by G418 using a fluorescence microscope. (A-D) Fluorescent light, x200. 996si, SGC-996 cells transfected with siRNA targeting TNF-α; 996NC, SGC-996 cells transfected with negative control.
mediated method to silence TNF-α in order to characterize the biological effects of TNF-α in the SGC-996 cells. DNA sequencing results verified that TNF-α siRNA plasmid construction was successful. We obtained stably transfected cells using G418 after 2 weeks, as shown by a screening test. RT-PCR revealed a decrease in TNF-α mRNA levels in the siRNA-transfected cells, while the levels of the β-actin gene maintained relatively unaltered and mock transfection or transfection with the C-N/siRNA vector had no effect on TNF-α mRNA expression (Fig. 4A). We obtained stably transfected SGC-996 cells by siRNA targeting TNF-α using G418 after 2 weeks, as shown by a screening test; these stably transfected cells were used for the following experiments. RT-PCR and western blot analysis indicated that autocrine TNF-α mRNA and protein levels were markedly inhibited in the siRNA-transfected SGC-996 (SGC-996si) cells. Semiquantitative analysis revealed that the TNF-α mRNA and protein expression in the SGC-996si group was markedly suppressed (Fig. 4).

Autocrine TNF-α protein levels in the untransfected SGC-996, TNF-α siRNA-transfected SGC-996 and SGC-996NC cell culture supernatants. We then analyzed the autocrine TNF-α protein levels in all cell culture supernatants of the untransfected SGC-996, TNF-α siRNA-transfected SGC-996 and SGC-996NC-transfected cells (Fig. 5). Consistent with the mRNA levels, ELISA analysis revealed that when compared to the untransfected SGC-996 and SGC-996NC-transfected cells, the TNF-α siRNA-transfected SGC-996 cells showed a marked inhibition in the production of autocrine TNF-α protein. By contrast, no transfection (SGC-996) or transfection with the negative control (SGC-996NC) had no effect on autocrine TNF-α protein levels (P<0.05).

Knockdown of TNF-α decreases the proliferation of SGC-996 cells in vitro. To determine whether the endogenous TNF-α promotes cancer cell proliferation, we first treated the human SGC-996 cells with siRNA directed against TNF-α. We transfected the SGC-996 cells with TNF-α siRNA to induce the downregulation of TNF-α gene expression with C-N/siRNA and mock-treated groups were used as controls. We examined cell proliferation at 1, 2, 3, 4 and 5 days by MTT assay. Compared to the C-N/siRNA-transfected cells and the untransfected cells, cell proliferation in the TNF-α siRNA-transfected group was slower (P<0.05) (Fig. 6). The data from the in vitro cell proliferation assay indicated that the growth of the cells in the TNF-α siRNA-transfected group was markedly reduced compared with the untreated group, which was the same as the growth of the C-N/siRNA-transfected group. These data support the autocrine role of TNF-α in affecting the proliferation of gallbladder cancer cells.

TNF-α knockdown influences gallbladder cancer cell migration and invasiveness. To determine whether the migration and invasiveness of the SGC-996 cells depends on endogenously secreted TNF-α, we used Transwell assay to examine the effects of the knockdown of the TNF-α gene in the SGC-996 cells. Following staining with H&E, 5 different fields (x400, magnification) were counted to test the numbers of migrated and invaded cells. The total number of cells in the TNF-α siRNA group that migrated and invaded through
the Transwell polycarbonate filter was significantly lower than that of the cells in the SGC-996 (untreated) group (Figs. 7 and 8) (P<0.05), which was similar to the number of cells in the C-N/siRNA group. These data suggest that the function of gallbladder cancer cell-derived TNF-α plays an important role in the migration and invasion of gallbladder cancer cells.

TNF-α knockdown does not increase the apoptosis of SGC-996 cells. To investigate whether the induced effects of TNF-α gene silencing on cell viability were due to apoptosis, we employed flow cytometry (FCM) after the cells were stained with Annexin V-PE/7-aminoactinomycin D. The untransfected SGC-996, TNF-α siRNA-transfected SGC-996 cells and the
SGC-996NC-transfected cells exhibited a similar rate of apoptosis (Fig. 9).

**Discussion**

In 1975, Carswell found a factor that can rapidly cause hemorrhaging and tumor necrosis, named TNF. Thus, TNF was initially identified and named as such, as it can cause tumor necrosis.

TNF-α knockdown decreases the activity of the TNF-α-AKT-NF-κB-Bcl-2 pathway, but does not promote the occurrence of apoptosis. To investigate the mechanisms of TNF-α silencing responsible for the decrease in growth and invasion, we assessed the changes in AKT, p-AKT, NF-κB (p65), p-NF-κB (p-p65), Bcl-2 and Bax protein levels. These proteins are vital to the survival of gallbladder cancer cells. The western blot analysis results indicated that the AKT, p-AKT, NF-κB (p65), p-NF-κB (p-p65) and Bcl-2 protein levels in the SGC-996si cells decreased (P<0.05) in comparison to the SGC-996NC-transfected and untransfected SGC-996 cells. We also examined the expression of the Bax gene, which can promote the apoptosis of gallbladder cancer cells, and found that TNF-α silencing did not significantly increase the expression of the Bax gene (P>0.05) (Fig. 10).
necrosis (26). TNF-α, a very important inflammatory cytokine with diverse biological activities, such as the maintenance and homeostasis of host defence and the immune system, has been shown to be involved in malignant disease. TNF-α can promote cancer cell proliferation and invasion and it is mainly produced by macrophages. Cellular responses to TNF-α are mediated through its receptors, TNFR1 and TNFR2. The expression of each receptor is independently regulated on the surface of cells. The ability of TNF-α receptors to interact with both identical and different downstream signaling pathways explains their respective functions. TNF-α activates pathways leading to different cell functions (27), such as cell survival and proliferation, expression of inflammatory genes and cell death. TNFR1 can signal each of these biological effects and plays a crucial role in cell survival and proliferation through the pathways of NF-κB and AP-1 (28,29).

To our knowledge, this study is the first to demonstrate the role of tumor-derived TNF-α in promoting the invasion and proliferation of human gallbladder cancer cells. We further investigated the possible mechanisms underlying this process. We determined whether TNF-α was expressed in two different gallbladder cancer cell lines (NOZ and SGC-996). We found that the mRNA and protein expression levels of TNF-α in the SGC-996 cells were higher compared to the levels in the NOZ...
cells. Thus, on the basis of our findings and those of previous studies (5,11,23,24), tumor-derived TNF-α may play an important role in gallbladder tumor cell proliferation and invasion.

We examined cell proliferation at 1, 2, 3, 4 and 5 days by MTT assay. Compared with the C-N/siRNA and untreated groups, cell proliferation in the TNF-α siRNA group was slower. The data from the in vitro cell proliferation assay indicated that the growth of the cells in the TNF-α siRNA group was markedly reduced compared with the untreated group and the C-N/siRNA group. This result is different from that of a previous study on ovarian cancer, in which the authors concluded that TNF-α RNAi cells grew at a similar rate to normal cells (11). We repeated our experiment and found that the results were consistent in the gallbladder cancer cells. The reasons for this phenomenon require further investigation.

A number of studies have reported that TNF-α can induce the expression of MMPs, interleukin (IL)-8, CXС chemokine receptor type 4 (CXCR), VEGF and MCP-1, thus enhancing tumor cell invasion and metastasis (17,18,20). Our research team also found that CXCR and VEGF-C/D promote gallbladder cancer cell proliferation and invasion (30-32). In this study, we found that the migration and invasion ability was inhibited when the TNF-α gene was silenced in vitro. This suggests that tumor-derived TNF-α exerts a profound effect on migration and invasion. As we used the RNAi technology to silence the TNF-α gene in SGC-996 cells, the expression of the cytokines, MMPs, IL-8, CXCR, VEGF and MCP-1, was decreased in the gallbladder cells (data not shown). In the present study, to determine whether the suppressive effects of TNF-α gene silencing on cell viability were due to apoptosis, we employed flow cytometry after the cells were stained with red fluorescence Annexin V-PE/7-aminocainomycin D. The untransfected SGC-996, TNF-α siRNA-transfected SGC-996 and SGC-996NC-transfected cells exhibited a similar rate of apoptosis. Further studies are required to elucidate the specific mechanisms responsible for this phenomenon.

In this study, we assessed the changes in AKT, p-AKT, NF-kB (p65), p-AKT, NF-kB (p65), Bcl-2 and Bax protein expression. These proteins are vital to the survival of gallbladder cancer cells. The western blot analysis results indicated that AKT, p-AKT, NF-kB (p65), p-AKT, NF-kB (p65) and Bcl-2 protein levels in the SGC-996si cells were decreased compared with those in the SGC-996NC-transfected and untransfected SGC-996 cells. We also examined the expression of Bax, which can promote the apoptosis of gallbladder cancer cells, and found that TNF-α silencing did not significantly increase the expression of the Bax gene.

In conclusion, in the present study, we verify the biological behavior of gallbladder cancer cell-derived TNF-α. We provide evidence that the reduction of autocrine TNF-α in gallbladder cancer cells can exert inhibitory effects on the ability of the cells to grow and migrate in vitro. This provides further evidence that targeting TNF-α and its intracellular pathways may prove useful in the treatment of gallbladder cancer.

Acknowledgements

This study was supported by grants from the National Natural Science Foundation of China (no. 81272373), the Key Project of Science and Technology Research Program in Fujian Province (no. 2009Y0024) and the Key Project of Science Research in Fujian Medical University (no. 09ZD017), and the National Clinical Key Specialty Construction Project (General Surgery) of China.

References

1. Donohue JH, Stewart AK and Menck HR: The National Cancer Data Base report on carcinoma of the gallbladder, 1989-1995. Cancer 83: 2618-2628, 1998.
2. Cunha-Filho P, Gainheiro J and Cucchiaro G: Surgical treatment of 724 carcinomas of the gallbladder. Results of the French Surgical Association Survey. Ann Surg 219: 275-280, 1994.
3. Bartlett DL, Fong Y, Fortner JG, Brennan MF and Blumgart LH: Long-term results after resection for gallbladder cancer. Implications for staging and management. Ann Surg 224: 639-646, 1996.
4. Eggerts JH, Cloosters V, Noack A, et al: Anti-tumor necrosis factor therapy inhibits pancreatic tumor growth and metastasis. Cancer Res 68: 1443-1450, 2008.
5. Soria G, Abraham B, Kucuk U and Aharinejad S: Colon cancer cell-derived tumor necrosis factor-alpha mediates the tumor growth-promoting response in macrophages by up-regulating the colony-stimulating factor-1 pathway. Cancer Res 67: 1038-1045, 2007.
6. Stathopoulos GT, Kollintza A, Moschos C, et al: Tumor necrosis factor-alpha promotes malignant pleural effusion. Cancer Res 67: 9825-9834, 2007.
7. Scott KA, Moore RJ, Arnott CH, et al: An anti-tumor necrosis factor-alpha antibody inhibits the development of experimental skin tumors. Mol Cancer Ther 2: 445-451, 2003.
8. Michalaki V, Syrigos K, Charles P and Waxman J: Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer. Br J Cancer 90: 2312-2316, 2004.
9. Soria G, Ofri-Shahak M, Han J, et al: Inflammatory mediators in breast cancer: coordinated expression of TNFα and IL-1β with CCL2 & CCL5 and effects on epithelial-to-mesenchymal transition. BMC Cancer 11: 130, 2011.
10. Radhakrishnan P, Chachadi V, Lin MF, Singh R, Kannagi R and Cheng PW: TNFα enhances the motility and invasiveness of prostatic cancer cells by stimulating the expression of selective glycosyl- and sulfotransferase genes involved in the synthesis of selectin ligands. Biochem Biophys Res Commun 409: 436-441, 2011.
11. Kulbe H, Thompson R, Wilson JL, et al: The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. Cancer Res 67: 585-592, 2007.
12. Akiyama M, Hideshima T, Hayashi T, et al: Nuclear factor-kappaB p65 mediates tumor necrosis factor-alpha-induced nuclear translocation of telomerase reverse transcriptase protein. Cancer Res 63: 18-21, 2003.
13. Li J, Sejas DP, Zhang X, et al: TNF-alpha induces leukemic clonal evolution ex vivo in Fanconi anemia group C murine stem cells. J Clin Invest 117: 3283-3295, 2007.
14. Yan B, Wang H, Rabbani ZN, et al: Tumor necrosis factor-alpha is a potent endogenous mutagen that promotes cellular transformation. Cancer Res 66: 11565-11570, 2006.
15. Komori J, Marusawa H, Machimoto T, et al: Activation-induced cytidine deaminase links bile duct inflammation to human cholangiocarcinoma. Hepatology 47: 888-896, 2008.
16. Li B, Vincent A, Cates J, Brantley-Sieders DM, Polk DB and Young PP: Low levels of tumor necrosis factor alpha increase tumor growth by inducing an endothelial phenotype of monocytes recruited to the tumor site. Cancer Res 69: 338-348, 2009.
17. Hagemann T, Wilson J, Kulbe H, et al: Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK. J Immunol 175: 1197-1205, 2005.
18. Kulbe H, Hagemann T, Szlosarek PW, Balkwill FR and Wilson JL: The inflammatory cytokine tumor necrosis factor-alpha regulates chemokine receptor expression on ovarian cancer cells. Cancer Res 65: 10355-10362, 2005.
19. Chua HL, Bhat-Nakhati P, Clare SE, Morimiya A, Badve S and Nakhati H: NF-kappaB represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammmary epithelial cells: potential involvement of ZEB-1 and ZEB-2. Oncogene 26: 711-724, 2007.
20. Johnston DA, Dong B and Hughes CC: TNF induction of jagged-1 in endothelial cells is NFkappaB-dependent. Gene 435: 36-44, 2009.
21. Cox GW, Melillo G, Chattopadhyay U, Mullet D, Fertel RH and Varesio L: Tumor necrosis factor-alpha-dependent production of reactive nitrogen intermediates mediates IFN-gamma plus IL-2-induced murine macrophage tumorcidal activity. J Immunol 149: 3290-3296, 1992.
22. Balkwill F: Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev 13: 135-141, 2002.
23. Naylor MS, Stamp GW, Foulkes WD, Eccles D and Balkwill FR: Tumor necrosis factor and its receptors in human ovarian cancer. Potential role in disease progression. J Clin Invest 91: 2194-2206, 1993.
25. Homma S, Hasumura S, Nagamori S and Kameda H: Establishment and characterization of a human gall bladder carcinoma cell line NOZ. Hum Cell 1: 95-97, 1988 (In Japanese).
26. Carwell EA, Old LJ, Kassell RL, Green S, Fiore N and Williamson B: An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA: 72: 3666-3670, 1975.